Q&A with Dr. Yongbin Liu: Working to Overcome Drug-Resistant Cancers
Traditional cancer treatment involves surgery followed by chemotherapy. However, some cancer patients eventually develop resistance to chemotherapy drugs and experience cancer recurrence. In addition, current chemo drugs have high levels of toxicity and therefore have severe side effects for patients.
Yongbin Liu, PhD, a postdoctoral fellow at Houston Methodist Research Institute, is working to develop safer, more potent drugs that can overcome the limitations of current chemotherapy medicines. He received a 2023 PhRMA Foundation Postdoctoral Fellowship in Drug Discovery for his research on novel nanomedicine drugs that can conquer drug resistance and have a lower toxicity in order to better treat refractory cancers.
Watch this video to learn about Liu and his research.
Subscribe to our Blog!
The PhRMA Foundation's blog brings you the latest developments in health care value assessment.